Lifecore Biomedical, Inc. De Return on Equity (ROE) Growth & History (LFCR)
Lifecore Biomedical, Inc. De's return on equity was −612.08% for fiscal 2025.
View full Lifecore Biomedical, Inc. De company overviewLifecore Biomedical, Inc. De annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 · May 25 | 2025-05-25 | −612.08% | −951.19 pp |
| 2024 | 2024-05-26 | 339.11% | +577.32 pp |
| 2023 | 2023-05-28 | −238.21% | −157.65 pp |
| 2022 | 2022-05-29 | −80.56% | −65.60 pp |
| 2021 | 2021-05-30 | −14.96% | +0.32 pp |
| 2020 | 2020-05-31 | −15.28% | −15.43 pp |
| 2019 | 2019-05-26 | 0.16% | −10.21 pp |
| 2018 | 2018-05-27 | 10.36% | +5.52 pp |
| 2017 | 2017-05-28 | 4.84% | +10.27 pp |
| 2016 | 2016-05-29 | −5.43% | −11.85 pp |
| 2015 | 2015-05-31 | 6.43% | −3.60 pp |
| 2014 | 2014-05-25 | 10.03% | −3.72 pp |
| 2013 | 2013-05-28 | 13.75% | +4.87 pp |
| 2012 | 2012-05-27 | 8.88% | — |
Lifecore Biomedical, Inc. De quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-05-25 | −64.49% | −15.65 pp |
| Q3 2025 · Feb 23 | 2025-02-23 | −167.16% | −330.79 pp |
| Q2 2025 | 2024-11-24 | −114.18% | — |
| Q1 2025 | 2024-08-25 | −440.08% | — |
| Q4 2024 | 2024-05-26 | −48.85% | +206.32 pp |
| Q3 2024 | 2024-02-25 | 163.63% | +230.50 pp |
| Q4 2023 | 2023-05-28 | −255.17% | −207.42 pp |
| Q3 2023 | 2023-02-26 | −66.87% | −57.81 pp |
| Q2 2023 | 2022-11-27 | −16.57% | +5.41 pp |
| Q1 2023 | 2022-08-28 | −13.04% | −8.30 pp |
| Q4 2022 | 2022-05-29 | −47.74% | −47.11 pp |
| Q3 2022 | 2022-02-27 | −9.06% | −5.68 pp |
| Q2 2022 | 2021-11-28 | −21.98% | −16.57 pp |
| Q1 2022 | 2021-08-29 | −4.74% | +0.76 pp |
| Q4 2021 | 2021-05-30 | −0.63% | +5.71 pp |
| Q3 2021 | 2021-02-28 | −3.37% | +1.17 pp |
| Q2 2021 | 2020-11-29 | −5.40% | −2.83 pp |
| Q1 2021 | 2020-08-30 | −5.50% | −3.72 pp |
| Q4 2020 | 2020-05-31 | −6.35% | −6.25 pp |
| Q3 2020 | 2020-02-23 | −4.55% | −4.95 pp |
| Q2 2020 | 2019-11-24 | −2.57% | −2.34 pp |
| Q1 2020 | 2019-08-25 | −1.79% | −1.86 pp |
| Q4 2019 | 2019-05-26 | −0.10% | −2.53 pp |
| Q3 2019 | 2019-02-24 | 0.41% | −6.30 pp |
| Q2 2019 | 2018-11-25 | −0.23% | −0.44 pp |
| Q1 2019 | 2018-08-26 | 0.08% | −0.87 pp |
| Q4 2018 | 2018-05-27 | 2.44% | +1.35 pp |
| Q3 2018 | 2018-02-25 | 6.71% | +5.12 pp |
| Q2 2018 | 2017-11-26 | 0.21% | −0.40 pp |
| Q1 2018 | 2017-08-27 | 0.94% | −0.61 pp |
| Q4 2017 | 2017-05-28 | 1.09% | −1.18 pp |
| Q3 2017 | 2017-02-26 | 1.59% | +11.44 pp |
| Q2 2017 | 2016-11-27 | 0.61% | −0.22 pp |
| Q1 2017 | 2016-08-28 | 1.55% | +0.22 pp |
| Q4 2016 | 2016-05-29 | 2.27% | +0.33 pp |
| Q3 2016 | 2016-02-28 | −9.85% | −11.63 pp |
| Q2 2016 | 2015-11-29 | 0.83% | −0.72 pp |
| Q1 2016 | 2015-08-30 | 1.34% | +0.19 pp |
| Q4 2015 | 2015-05-31 | 1.94% | −0.32 pp |
| Q3 2015 | 2015-03-01 | 1.78% | −1.53 pp |
| Q2 2015 | 2014-11-30 | 1.55% | −0.30 pp |
| Q1 2015 | 2014-08-31 | 1.15% | −1.47 pp |
| Q4 2014 | 2014-05-25 | 2.26% | — |
| Q3 2014 | 2014-02-23 | 3.31% | +0.49 pp |
| Q2 2014 | 2013-11-24 | 1.85% | −3.79 pp |
| Q1 2014 | 2013-08-25 | 2.62% | — |
| Q3 2013 | 2013-02-24 | 2.82% | −0.48 pp |
| Q2 2013 · Nov 25 | 2012-11-25 | 5.64% | +3.26 pp |
| Q4 2012 | 2012-05-27 | 1.87% | — |
| Q3 2012 | 2012-02-26 | 3.30% | — |
| Q2 2012 | 2011-11-27 | 2.38% | — |
| Q1 2012 | 2011-08-28 | 1.32% | — |
Lifecore Biomedical, Inc. De return on equity trends
Over the last five fiscal years, Lifecore Biomedical, Inc. De's return on equity decreased from −15.28% to −612.08%, a change of −596.80 percentage points. The latest reported quarter, Q4 2025, shows −64.49%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lifecore Biomedical, Inc. De source filings ↗